Status:
COMPLETED
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Systemic Sclerosis
Systemic Scleroderma
Eligibility:
All Genders
18-66 years
Brief Summary
Eosinophils are involved in tissue remodeling and fibrosis in many inflammatory diseases. Systemic sclerosis (SSc) is an autoimmune disease with fibrotic skin and lung complications. The profibrosing ...
Detailed Description
it will assess the activation state of blood eosinophils in SSc patients compared to healthy controls (ECP production in vitro, surface activation markers, whole transcriptome array, ..). it will als...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- For SSc patients:
- Meeting the 2013 ACR-EULAR criteria for diffuse SSc (n = 20) and limited SSc (n = 20)
- Having signed the informed consent
- Eosinophils ≥ 0.1 G / L on the last blood test (\<3 months)
- For healthy subjects:
- Without chronic pathology requiring long-term treatment
- Eosinophils between 0.1 and 0.4 G / L on recent blood test (\<3 months)
- Exclusion Criteria for patients and controls:
- Patient with an infection, state of emergency or progressive neoplastic pathology
- Pregnant or lactating women
- History of atopy (allergic asthma, atopic eczema, allergic rhinitis, allergic conjunctivitis)
- Allergy to local anesthetics (for scleroderma patients only)
- Taking into account a minimum weight of 50 kg and in the absence of cardiorespiratory effects of scleroderma, only patients with at least 10 g of hemoglobin will be included
Exclusion
Key Trial Info
Start Date :
October 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 5 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03816189
Start Date
October 3 2018
End Date
April 5 2022
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Claude Huriez, CHU
Lille, France